Earnings ·
Reports Q3 net loss of $73.6M and raises R&D spend to $59.8M as EMPEROR study nears primary endpoint
STOKStoke Therapeutics, Inc.
Stoke Therapeutics reported a third-quarter net loss of $73.6 million, or $1.08 per share, compared to a $38.3 million loss in the prior-year period. Revenue rose 6% to $11.3 million from licensing agreements with Acadia and Biogen. Research and development expenses increased significantly to $59.8 million due to advancing zorevunersen activities. The company holds $358.8 million in cash, expected to fund operations into early 2028. Clinically, the Phase 3 EMPEROR study for Dravet syndrome has completed enrollment of 162 patients, with approximately 110 reaching the Week 28 primary endpoint and data readout anticipated in Q3 2027. The company also provided updates on STK-002 for ADOA and an FDA meeting regarding NDA submission strategy. Stoke Therapeutics is a biotechnology company developing RNA medicines to restore protein expression.